Swiss pharma giant Novartis is taking legal action against the Australian cancer care provider as a dispute over how to fund ...

The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NMSCs, ovarian ...

Beyoncé’s dad teamed up with ZERO Prostate Cancer to tackle the disease. Learn how this game-changing campaign is breaking stigma, expanding screenings and saving lives.

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

In this video, Tanya Dorff, MD discusses the current state of the pipeline for developing castration-resistant prostate cancer treatments.

In this video, Tanya Dorff, MD discusses the latest advancements in the study and treatment of castration-resistant prostate cancer.

A new at-home urine test for prostate cancer developed by Michigan researchers aims to encourage more men to undergo ...

Myriad Genetics (MYGN) and PATHOMIQ entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI ...

Therapeutic Nuclear Medicines MarketThe therapeutic nuclear medicine market is projected to grow from USD 1.32 billion in ...

The rising global cancer incidence is a key factor driving the CD47 inhibitors market, as the demand for novel therapies grows. Recent clinical trial ...

Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment ...